You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Bacteriocins as Potential Anticancer Agents
|
|---|---|
| Published in |
Frontiers in Pharmacology, November 2015
|
| DOI | 10.3389/fphar.2015.00272 |
| Pubmed ID | |
| Authors |
Sumanpreet Kaur, Sukhraj Kaur |
| Abstract |
Cancer remains one of the leading causes of deaths worldwide, despite advances in its treatment and detection. The conventional chemotherapeutic agents used for the treatment of cancer have non-specific toxicity toward normal body cells that cause various side effects. Secondly, cancer cells are known to develop chemotherapy resistance in due course of treatment. Thus, the demand for novel anti-cancer agents is increasing day by day. Some of the experimental studies have reported the therapeutic potential of bacteriocins against various types of cancer cell lines. Bacteriocins are ribosomally-synthesized cationic peptides secreted by almost all groups of bacteria. Some bacteriocins have shown selective cytotoxicity toward cancer cells as compared to normal cells. This makes them promising candidates for further investigation and clinical trials. In this review article, we present the overview of the various cancer cell-specific cytotoxic bacteriocins, their mode of action and efficacies. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 4 | 57% |
| Switzerland | 1 | 14% |
| Unknown | 2 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 71% |
| Scientists | 2 | 29% |
Mendeley readers
The data shown below were compiled from readership statistics for 328 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| Netherlands | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 325 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 52 | 16% |
| Student > Master | 42 | 13% |
| Student > Bachelor | 34 | 10% |
| Researcher | 26 | 8% |
| Other | 15 | 5% |
| Other | 48 | 15% |
| Unknown | 111 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 78 | 24% |
| Agricultural and Biological Sciences | 49 | 15% |
| Immunology and Microbiology | 21 | 6% |
| Medicine and Dentistry | 13 | 4% |
| Chemistry | 11 | 3% |
| Other | 36 | 11% |
| Unknown | 120 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2022.
All research outputs
#3,825,236
of 23,507,888 outputs
Outputs from Frontiers in Pharmacology
#1,724
of 17,073 outputs
Outputs of similar age
#52,290
of 284,327 outputs
Outputs of similar age from Frontiers in Pharmacology
#14
of 86 outputs
Altmetric has tracked 23,507,888 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,073 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,327 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.